A Phase I/IIa Open Label, Non-Randomized, Multicenter Study of CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Aenocarcinoma

  • End date
    Feb 15, 2025
  • participants needed
  • sponsor
    Celularity Incorporated
Updated on 27 October 2022


This study will find the maximum tolerated dose (MTD) of CYNK-101 which contains Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded. CYNK-101 will be administered as first-line treatment, following induction therapy consisting of Pembrolizumab, Trastuzumab and a Fluoropyrimidine / Platinum based Chemotherapy regimen. Patients are required to undergo a biopsy for confirmation of HER2 positivity defined as either IHC 3+ or IHC 2+ with a positive fluorescent in-situ hybridization (FISH) or FISH + alone. The safety of this treatment will be evaluated, and researchers will want to learn if NK cells will help in treating patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma.

Condition Metastatic HER2 Positive Gastroesophageal Junction Cancer
Treatment cyclophosphamide, Fludarabine, Trastuzumab, Pembrolizumab, MESNA, Recombinant human interleukin-2, CYNK-101
Clinical Study IdentifierNCT05207722
SponsorCelularity Incorporated
Last Modified on27 October 2022


Yes No Not Sure

Inclusion Criteria

Be at least 18 years of age on the day of signing informed consent
Have cytologically or histologically confirmed diagnosis for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-Positive Gastric or Gastroesophageal junction (G/GEJ) adenocarcinoma
• Patients who have received adjuvant therapy more than 12 months prior to
Visit 2 will be allowed to participate in the study. Any patient who has
completed an INDUCTION regimen prior to study entry and achieved best tumor
response as either (1) Stable Disease per RECIST after 6 cycles or (2)
Progressive Disease per RECIST and meets all other inclusion/exclusion
criteria per protocol, will be eligible for enrollment in this clinical trial
Patients will be required to undergo a biopsy for confirmation of HER2 expression prior to study entry
HER2 overexpression is defined by immunohistochemistry (IHC) or in situ hybridization (ISH) for amplification of HER2 gene
Patients must have either IHC 3+ or IHC 2+ with a positive fluorescent in-situ hybridization (FISH) or FISH + alone, as assessed locally on primary or metastatic tumor
Due to differences in tumor histopathology, use of FDA-approved tests, specific for Gastric Cancers, will be required when assessing HER2 Expression [HERCEPTIN package insert; 202120]
Have measurable disease as assessed by the investigator according to RECIST 1.1
[Eisenhauer EA et al, 200913]
Have a performance status of 0-1 on the Eastern Cooperative Oncology Group (ECOG) performance scale
Have a life expectancy of ≥ 6 months
Patients must agree to use a highly effective method of contraception from the start of the study until 1 year after the last dose of lymphodepletion or 4 months from last dose of pembrolizumab, or 6 months from last dose of trastuzumab; whichever comes later
Have adequate cardiac function, defined as left ventricular ejection fraction > 45% as determined by MUGA scan or ECHO and QT interval calculated according to the Fridericia method (≤ 470 ms for men and ≤480 ms for women)
Demonstrate adequate organ function by laboratory values as follows
Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
Platelet count ≥ 100 x 109/L
Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L
Calculated creatinine clearance (Cockcroft-Gault Formula) ≥ 50 mL/min
Total bilirubin ≤1.5 x ULN
Exception: Patients with Gilbert's disease total bilirubin ≤ 3.0 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN
Exception: AST and ALT ≤ 5 x ULN for patients with liver metastases
Prothrombin Time (PT) ≤ 1.5 x ULN unless patient is receiving anticoagulant therapy if PT or PTT is within therapeutic range of intended use of anticoagulants
activated Partial Thromboplastin Time (aPTT) ≤ 1.5 x ULN unless patient is receiving anticoagulant therapy if PT or PTT is within therapeutic range of intended use of anticoagulants

Exclusion Criteria

Patients who have received prior systemic therapy for locally advanced unresectable or metastatic disease
Has had major surgery, open biopsy, or significant traumatic injury within 28 days prior to Visit 2, or anticipation of the need for major surgery during the course of study treatment
Has had radiotherapy within 14 days prior to Visit 2
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
• Exceptions: Squamous or Basal cell carcinoma of the skin, superficial
bladder cancer, and prostate cancer not requiring treatment
Patients with symptomatic, untreated, or actively progressing CNS metastases. Patients with a history of CNS metastases are eligible if they have not received radiotherapy within 7 days or whole-brain radiation for the past 14 days. Patients should not be receiving ongoing treatment with either corticosteroids or anticonvulsants. Patients with new CNS metastases detected during the Screening period, may participate in the study if they receive radiotherapy or surgery resulting in stable metastatic disease
Has an active autoimmune disease that has required systemic treatment in the past 2 years
Patients with hypothyroidism who are on stable replacement therapy will be allowed
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy greater than 10 mg per day of prednisone or equivalent
• Patients who require replacement for adrenal insufficiency will be allowed
Has a history of (non-infectious) pneumonitis that requires steroids or current pneumonitis
Has a known history of active tuberculosis
Has an active infection requiring systemic therapy
Accumulation of pleural, ascitic, or pericardial fluid requiring drainage or diuretic drugs within 14 days prior to Visit 2. If the participant is receiving diuretic drugs for other reasons, it is acceptable
Has peripheral neuropathy > Grade 1
Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the trial
Has active or clinically significant cardiac disease including
History of myocarditis
History or presence of serious uncontrolled cardiac arrhythmias
Clinically significant resting bradycardia
Left ventricular ejection fraction (LVEF) as determined by echocardiogram (ECHO) < 45% or multiple gated acquisition scan (MUGA) < 45%
Any of the following within 6 months prior to the start of the study treatments
myocardial infarction (MI), severe/unstable angina, congestive heart failure (CHF)
cerebrovascular accident (CVA), transient ischemic attack (TIA)
Patients with history of human immunodeficiency virus (HIV) infection must be
Known active infection with hepatitis B, hepatitis C, SARS-CoV-2, or other viral
infections requiring systemic therapy
Patients having a potential hypersensitivity (≥ Grade 3) to pembrolizumab
trastuzumab, study chemotherapy agents, rhIL-2 and/or to any excipients, murine
proteins, or platinum-containing products. NOTE: any adverse events which has occurred
because of prior therapy MUST have resolved to ≤ Grade 1 according to CTCAE (NCI
Common Terminology Criteria for Adverse Events) Version 5 prior to study entry
Has had an allogeneic tissue/solid organ transplant
Immunized with live vaccine ≤ 28 days before Visit 2
Participation in study of investigational agent or device ≤ 28 day prior to Visit 2
Patient is pregnant or breastfeeding
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note